Company Analysis Cyclo Therapeutics, Inc.
1. Summary
Disadvantages
- Price (1.4 $) is higher than fair price (1.21 $)
- Dividends (0%) are below the sector average (0.5399%).
- The stock's return over the last year (-62.39%) is lower than the sector average (-37.33%).
- Current debt level 7.8% has increased over 5 years from 1.29%.
- The company's current efficiency (ROE=-421.64%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Cyclo Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -5.1% | -1.7% | 0.8% |
| 90 days | -16.9% | -40.1% | 6.4% |
| 1 year | -62.4% | -37.3% | 27.5% |
CYTH vs Sector: Cyclo Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -25.06% over the past year.
CYTH vs Market: Cyclo Therapeutics, Inc. has significantly underperformed the market by -89.86% over the past year.
Stable price: CYTH is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CYTH with weekly volatility of -1.2% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1.4 $) is higher than the fair price (1.21 $).
Price is higher than fair: The current price (1.4 $) is 13.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (6.11) is higher than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (6.11) is higher than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (27) is lower than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (27) is higher than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.04) is higher than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.04) is lower than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 25.07% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (25.07%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (-421.64%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-421.64%) is lower than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (-151.4%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-151.4%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
